Comparison of hypotensive effect and prevention to progression of diabetic nephrolopathy with Olmesartan and Ca channel blocker in patient of type 2 diabetes

Trial Profile

Comparison of hypotensive effect and prevention to progression of diabetic nephrolopathy with Olmesartan and Ca channel blocker in patient of type 2 diabetes

Recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2012

At a glance

  • Drugs Azelnidipine (Primary) ; Olmesartan medoxomil (Primary) ; Amlodipine
  • Indications Diabetic nephropathies; Hypertension; Type 2 diabetes mellitus
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Acronyms SORT
  • Most Recent Events

    • 08 Nov 2012 Lead trial centre deleted as reported by University Hospital Medical Information Network - Japan.
    • 29 Aug 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top